Smith & Nephew
Makes Truclear, a product that removes polyps, fibroids and other abnormal tissue from the uterus.
Launch date
Employees
Market cap
CAD18.5b
Enterprise valuation
CAD22.8b (Public information from Sep 2024)
Share price
$30.95 SNN
Company register number 00324357
Watford England (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 4.6b | 5.2b | 5.2b | 5.5b | 5.8b | 6.1b | 6.4b |
% growth | (11 %) | 14 % | - | 6 % | 5 % | 5 % | 5 % |
EBITDA | 904m | 1.2b | 943m | 1.2b | 1.4b | 1.6b | 1.7b |
% EBITDA margin | 20 % | 22 % | 18 % | 21 % | 25 % | 26 % | 27 % |
Profit | 448m | 524m | 223m | 263m | 462m | 640m | 764m |
% profit margin | 10 % | 10 % | 4 % | 5 % | 8 % | 10 % | 12 % |
EV / revenue | 4.4x | 3.4x | 2.7x | 2.7x | 2.8x | 2.6x | 2.4x |
EV / EBITDA | 22.1x | 14.9x | 15.0x | 12.4x | 11.1x | 9.9x | 9.0x |
R&D budget | 307m | 356m | 345m | 299m | - | - | - |
R&D % of revenue | 7 % | 7 % | 7 % | 5 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
$350m Valuation: $350m 0.3x EV/LTM EBITDA | Acquisition | ||
* | $204k | Post IPO Equity | |
Total Funding | - |
Related Content
Recent News about Smith & Nephew
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by Smith & Nephew
EditACQUISITION by Smith & Nephew Jun 2019
ACQUISITION by Smith & Nephew Nov 2023
ACQUISITION by Stryker Mar 2019
ACQUISITION by Smith & Nephew Feb 2014
ACQUISITION by Smith & Nephew Oct 2017
ACQUISITION by Smith & Nephew May 2012
ACQUISITION by Smith & Nephew Apr 2012
ACQUISITION by Smith & Nephew Nov 2015